A Paget’s disease, also known as Osteitis deformans, is a chronic bone disorder, which affects a single bone (monostotic) or multiple bones (poly-ostotic) resulting in abnormally long, weak, and brittle bone structure. Disorganized bone production or excessive bone breakdown are the major causes of the disease that may result in pain and fractures in joints around the damaged bone. The remolding of bone is disrupted in Paget's disease, resulting in brittle and thick bone. Most commonly involved bones include the femur, pelvis, spine, tibia, and skull .In addition, other medical problems associated with this disease include arthritis, kidney stones, nervous system issues, and vision loss. Majority of people with Paget's disease are asymptomatic, but some patients experience symptoms such bone pain, secondary osteoarthritis, bone deformities, excessive warmth, and neurologic problems.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future owing to the demand for vaccine and treatment
drugs for COVID-19. This, in turn, is expected to have a significant impact on the Paget’s disease treatment market.
Top Impacting Factors
Increase in prevalence of Paget’s disease among people across the world and surge in geriatric population are some factors that boost the market growth.
In addition, rise in awareness about health and government initiatives to improve healthcare infrastructure contribute toward the market growth. Moreover, increase in research and activities by key players to identify viral and genetic causes of Paget’s disease is expected to propel the market growth.
Furthermore, the approval of new and highly effective drugs for the treatment of the disease is projected to increase the uptake of drugs by patients and ultimately boost the market growth. Rise in number of cases related to arthritis and bone injuries is further fueling the market growth.
However, patent expiry of drugs such as Fosamax, Miacalcin, and Reclast is likely to hamper the growth of paget’s disease treatment market.
Market Trends
New Product Launches to Flourish the Market
In March 2020, EA Pharma Co., Ltd. and its parent company Eisai Co., Ltd. launched the MHLW (Ministry of Health, Labour and Welfare) approved “Actonel 17.5 mg tablets” for treatment of Paget’s disease of bone.
In May 2021, Leucadia Pharmaceuticals Inc. launched its latest FDA-approved generic, Calcitonin Salmon Injection, USP, Synthetic. The injection is therapeutically equivalent to MIACALCIN and it is used to treat osteoporosis in postmenopausal women and to treat Paget's disease. It is indicated for the early treatment of hypercalcemic emergencies when a rapid decrease in serum calcium is required.
Key Benefits of the Report
- This study presents the analytical depiction of the paget’s disease treatment market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the paget’s disease treatment market share.
- The current market is quantitatively analyzed to highlight the paget’s disease treatment market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the paget’s disease treatment market .
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Paget’s Disease Treatment Market Report
- Which are the leading players active in the paget’s disease treatment market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is paget’s disease treatment market?
- What is paget’s disease treatment market prediction in the future?
- Who are the leading global players in the paget’s disease treatment market?
- What are the current trends and predicted trends?
- What are the key benefits of the paget’s disease treatment market report?
Paget’s disease Treatment Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Route of Administration |
|
 By End User |
|
 By Region |
|
 Key Market Players | Mylan NV, Mallinckrodt Pharmaceuticals, Novartis AG, Teva Pharmaceutical Industries Ltd., Neopharma Inc., Fresenius Kabi, Allergan, Sun Pharmaceutical Industries Ltd., Sanofi S.A.,, Merck KGaA |
Loading Table Of Content...
